logo

Preimplantation Genetic Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Market is Segmented by Test Type, Products and Services, Application (HLA Typing, IVF Prognosis, Aneuploidy Screening, and Other Applications), End User, and Geography.

Home Industry Reports Healthcare Preimplantation Genetic Testing Market - Growth, Trends, COVID-19 Impact, and Fo ...

Pre-Implantation Genetic Testing Market Snapshot

Pre-Implantation Genetic Testing Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period. The major factor attributing to the growth of the market is a rising awareness among parents regarding advancements in diagnostics with a huge volume of neonatal deaths due to complications during childbirth. The growing prevalence of congenital genetic diseases like Edwards syndrome, and common pediatric respiratory disorders such as pneumonia, and asthma are observed in recent years. As per the estimates published by the United Nations Children's Fund (UNICEF) in November 2018, about 3 million deaths occurred due to pediatric pneumonia worldwide each year. These abnormalities occur almost exclusively in couples with hereditary disorders, which was observed to occur majorly in industrialized nations. Thus, increased demand for earlier diagnosis and a rise in government initiatives to control the healthcare burden is likely to drive the pre-implantation genetic testing market.

Scope of the Report

Preimplantation genetic testing is genetic profiling of embryos employed before implantation in IVF workflow, and sometimes even of oocytes before fertilization for a successful pregnancy. These tests help in making the right decision for the couples, who are at risk of hereditary disorders, whether to terminate the pregnancy or not, by detecting the presence of disorder during the course of gestation. These tests also benefit women in IVF cycles, who faced miscarriages earlier or those who had the last pregnancy with an abnormality in chromosomes.

Test Type
Preimplantation Genetic Diagnosis (PGD)
Preimplantation Genetic Screening (PGS)
Product and Service
Instruments
Reagents and Consumables
Software and Services
Application
HLA Typing
IVF Prognosis
Aneuploidy Screening
Other Applications
End User
Hospitals and Diagnostic Labs
Maternity Centers and Fertility Clinics
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

HLA Typing by Application Segment is Expected to Hold the Major Market Share in the Preimplantation Genetic Testing Market

The HLA typing by application segment is expected to account for the largest held the largest of the pre-implantation genetic testing market. Dominance can be owing to a rising volume of patients with damaged bone marrow or defective immune system. This results in an increased volume of hematopoietic stem cell transplantations (HSCT), necessitating the tests. Also, their increased application in evaluating interconnected matched donors and unrelated donors for safer HSCT is expected to drive the growth of the segment. On the other hand, inherited genetic disease testing is anticipated to witness the highest CAGR during the forecast period. The lucrative growth can be due to their ability to detect diseases in offspring and increased awareness among the public about the inheritance of these diseases by future generations. Furthermore, steep rising incidences of inherited genetic diseases, such as Marfan syndrome, cystic fibrosis, fragile X syndrome hemoglobin disorders, and others, are driving the growth of the segment.

Pre-Implantation Genetic Testing Market

North America Dominates the Market and it is Expected to do the Same in the Forecast Period

North America is expected to dominate the pre-implantation genetic testing market. The dominance is owing to a growing volume of chromosome abnormality cases leading to various genetic disorders. Aneuploidy is the most common causing Down syndrome among newborn babies in the united states, which holds the major revenue share in the North American market. According to the World Health Organization report published in 2018, down syndrome continues to be the most common chromosomal disorder affecting 6,000 babies born in the United States each year. This, in turn, resulted in high demand for earlier diagnosis to identify the genetic defects in embryos drive the market in the region. Launch of new products by key players and a rise in improvements in healthcare infrastructure in the United States generates more revenue. Rise in government initiatives to create awareness in public and growing preference among couples for these tests during IVF and other artificial insemination procedures further stimulate the growth of the preimplantation genetic testing market in the region.

Pre-Implantation Genetic Testing Market

Competitive Landscape

The preimplantation genetic testing market is moderately competitive and consists of several major players. Few of the key players dominating the market are following various strategies like an increased focus on R&D and the launch of new products. In October 2019, PerkinElmer launched PG-Seq Rapid Non-Invasive Pre-implantation Genetic Testing Kit for Aneuploidy (PGT-A). It is a non-invasive alternative to conventional IVF embryo biopsies, which is expected to impact the market positively. Some of the major companies currently dominating the market are The Cooper Companies Inc., Illumina Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., and Bioarray SL.

Pre-Implantation Genetic Testing Market.png

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Genetic Diseases Like Patau Syndrome, Edwards Syndrome, and Down Syndrome

      2. 4.2.2 Increased Government Initiatives to Create Awareness and R&D Activities to Develop Advanced Diagnostic Devices

    3. 4.3 Market Restraints

      1. 4.3.1 Small Size of Study Population and Ethical Concerns

      2. 4.3.2 Highly Expensive Testing Procedures

      3. 4.3.3 Unfavorable Regulatory Framework and Challenges During Development Stage

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Test Type

      1. 5.1.1 Preimplantation Genetic Diagnosis (PGD)

      2. 5.1.2 Preimplantation Genetic Screening (PGS)

    2. 5.2 Product and Service

      1. 5.2.1 Instruments

      2. 5.2.2 Reagents and Consumables

      3. 5.2.3 Software and Services

    3. 5.3 Application

      1. 5.3.1 HLA Typing

      2. 5.3.2 IVF Prognosis

      3. 5.3.3 Aneuploidy Screening

      4. 5.3.4 Other Applications

    4. 5.4 End User

      1. 5.4.1 Hospitals and Diagnostic Labs

      2. 5.4.2 Maternity Centers and Fertility Clinics

      3. 5.4.3 Other End Users

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle-East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle-East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 The Cooper Companies Inc.

      2. 6.1.2 Illumina Inc.

      3. 6.1.3 Thermo Fisher Scientific Inc.

      4. 6.1.4 Quest Diagnostics Inc.

      5. 6.1.5 PerkinElmer Inc.

      6. 6.1.6 Invitae Corp.

      7. 6.1.7 Natera Inc.

      8. 6.1.8 Igenomix Sl

      9. 6.1.9 Bioarray SL

      10. 6.1.10 Genea Ltd

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Preimplantation Genetic Testing Market market is studied from 2018 - 2026.

The Preimplantation Genetic Testing Market is growing at a CAGR of 10.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

The Cooper Companies Inc, Illumina Inc, Thermo Fisher Scientific Inc, PerkinElmer Inc, Bioarray S L, Bioarray S L are the major companies operating in Preimplantation Genetic Testing Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!